{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:49:55Z","timestamp":1792226995174,"version":"4.4.0"},"reference-count":29,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>The COVID-19 pandemic impacted the timely diagnosis of cancer, which persisted as the second leading cause of death in the US throughout the pandemic.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate the disruption and potential recovery in cancer detection during the first (2020) and second (2021) years of the COVID-19 pandemic.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This cross-sectional study involved an epidemiologic analysis of nationally representative, population-based cancer incidence data from the Surveillance, Epidemiology, and End Results (SEER) Program. Included patients were diagnosed with incident cancer from January 1, 2000, through December 31, 2021. The analysis was conducted in May 2024 using the April 2024 SEER data release, which includes incidence data through December 31, 2021.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Diagnosis of cancer during the first 2 years of the COVID-19 pandemic (2020, 2021).<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Difference between the expected and observed cancer incidence in 2020 compared with 2021, with additional analyses by demographic subgroups (sex, race and ethnicity, and age group) and community (county-level) characteristics.<\/jats:p><\/jats:sec>Results<\/jats:title>The analysis included 15\u202f831\u202f912 patients diagnosed with invasive cancer between 2000 and 2021, including 759\u202f810 patients in 2020 and 825\u202f645 in 2021. The median age was 65 years (IQR, 56-75 years), and 51.0% were male. The percentage difference between the expected and observed cancer incidence was \u22128.6% (95% CI, \u22129.1% to \u22128.1%) in 2020, with no significant difference in 2021 (\u22120.2%; 95% CI, \u22120.7% to 0.4%). These translated to a cumulative (2020-2021) deficit in observed vs expected cases of \u2212127\u202f931 (95% CI, \u2212139\u202f206 to \u2212116\u202f655). Subgroup analyses revealed that incidence rates remained substantially depressed from expected rates into 2021 for patients living in the most rural counties (\u22124.9%; 95% CI, \u22126.7% to \u22123.1%). The cancer sites with the largest cumulative deficit in observed vs expected cases included lung and bronchus (\u221224\u202f940 cases; 95% CI, \u221228\u202f936 to \u221220\u202f944 cases), prostate (\u221214\u202f104 cases; 95% CI, \u221227\u202f472 to \u2212736 cases), and melanoma (\u221210\u202f274 cases; 95% CI, \u221212\u202f825 to \u22127724 cases).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>This cross-sectional study of nationally representative registry data found that cancer incidence recovered meaningfully in 2021 following substantial disruptions in 2020. However, incidence rates need to recover further to address the substantial number of patients with undiagnosed cancer during the pandemic.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.39263","type":"journal-article","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T15:01:09Z","timestamp":1728918069000},"page":"e2439263","source":"Crossref","is-referenced-by-count":22,"title":["Recovery From COVID-19\u2013Related Disruptions in Cancer Detection"],"prefix":"10.1001","volume":"7","author":[{"given":"Uriel","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Cedars-Sinai Medical Center, Los Angeles, California"},{"name":"Case Comprehensive Cancer Center, School of Medicine, Case Western Reserve University, Cleveland, Ohio"},{"name":"Department of Population and Quantitative Health Sciences, School of Medicine, Case Western Reserve University, Cleveland, Ohio"},{"name":"Center for Community Health Integration, School of Medicine, Case Western Reserve University, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnie","family":"Rose","sequence":"additional","affiliation":[{"name":"Case Comprehensive Cancer Center, School of Medicine, Case Western Reserve University, Cleveland, Ohio"},{"name":"Department of Population and Quantitative Health Sciences, School of Medicine, Case Western Reserve University, Cleveland, Ohio"},{"name":"Center for Community Health Integration, School of Medicine, Case Western Reserve University, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan T.","family":"Carroll","sequence":"additional","affiliation":[{"name":"Case Comprehensive Cancer Center, School of Medicine, Case Western Reserve University, Cleveland, Ohio"},{"name":"Department of Dermatology, University Hospitals Cleveland Medical Center, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard S.","family":"Hoehn","sequence":"additional","affiliation":[{"name":"Case Comprehensive Cancer Center, School of Medicine, Case Western Reserve University, Cleveland, Ohio"},{"name":"Division of Surgical Oncology, University Hospitals Cleveland Medical Center, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Chen","sequence":"additional","affiliation":[{"name":"Case Comprehensive Cancer Center, School of Medicine, Case Western Reserve University, Cleveland, Ohio"},{"name":"Department of Radiation Oncology, School of Medicine, University of California, Irvine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy S.","family":"Bordeaux","sequence":"additional","affiliation":[{"name":"Case Comprehensive Cancer Center, School of Medicine, Case Western Reserve University, Cleveland, Ohio"},{"name":"Department of Dermatology, University Hospitals Cleveland Medical Center, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siran M.","family":"Koroukian","sequence":"additional","affiliation":[{"name":"Case Comprehensive Cancer Center, School of Medicine, Case Western Reserve University, Cleveland, Ohio"},{"name":"Department of Population and Quantitative Health Sciences, School of Medicine, Case Western Reserve University, Cleveland, Ohio"},{"name":"Center for Community Health Integration, School of Medicine, Case Western Reserve University, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,10,14]]},"reference":[{"issue":"6","key":"zoi241131r1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.15490","article-title":"Changes in cancer screening in the US during the COVID-19 pandemic.","volume":"5","author":"Fedewa","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"17","key":"zoi241131r2","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1200\/JCO.22.01704","article-title":"Impact of the COVID-19 pandemic on cancer screening delays.","volume":"41","author":"Zhang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi241131r3","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1377\/hlthaff.2023.00767","article-title":"US cancer detection decreased nearly 9 percent during the first year of the COVID-19 pandemic.","volume":"43","author":"Kim","year":"2024","journal-title":"Health Aff (Millwood)"},{"issue":"4","key":"zoi241131r4","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1001\/jamaoncol.2023.6969","article-title":"Undiagnosed cancer cases in the US during the first 10 months of the COVID-19 pandemic.","volume":"10","author":"Burus","year":"2024","journal-title":"JAMA Oncol"},{"issue":"1","key":"zoi241131r5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1001\/jamaoncol.2023.4513","article-title":"Assessment of changes in cancer treatment during the first year of the COVID-19 pandemic in the US.","volume":"10","author":"Nogueira","year":"2024","journal-title":"JAMA Oncol"},{"issue":"1","key":"zoi241131r6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jamaoncol.2021.5148","article-title":"Evaluation of COVID-19 mortality and adverse outcomes in US patients with or without cancer.","volume":"8","author":"Chavez-MacGregor","year":"2022","journal-title":"JAMA Oncol"},{"issue":"1","key":"zoi241131r7","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1001\/jamaoncol.2023.5042","article-title":"Mortality and hospitalization risks in patients with cancer and the SARS-CoV-2 Omicron variant.","volume":"10","author":"Ofer","year":"2024","journal-title":"JAMA Oncol"},{"issue":"2","key":"zoi241131r8","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1093\/jnci\/djad205","article-title":"Cancer and COVID-19: US cancer incidence rates during the first year of the pandemic.","volume":"116","author":"Howlader","year":"2024","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"zoi241131r9","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1136\/medethics-2020-106227","article-title":"Whose life to save? scarce resources allocation in the COVID-19 outbreak.","volume":"46","author":"Mannelli","year":"2020","journal-title":"J Med Ethics"},{"issue":"2","key":"zoi241131r10","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s00148-020-00818-x","article-title":"Socio-demographic factors associated with self-protecting behavior during the COVID-19 pandemic.","volume":"34","author":"Papageorge","year":"2021","journal-title":"J Popul Econ"},{"issue":"3","key":"zoi241131r11","doi-asserted-by":"publisher","DOI":"10.1136\/fmch-2020-000530","article-title":"Telemedicine, the current COVID-19 pandemic and the future: a narrative review and perspectives moving forward in the USA.","volume":"8","author":"Kichloo","year":"2020","journal-title":"Fam Med Community Health"},{"issue":"4","key":"zoi241131r12","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/j.jaad.2020.07.024","article-title":"Guiding principles for prioritization of limited in-person dermatology appointments during the COVID-19 pandemic.","volume":"83","author":"Stoff","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"zoi241131r13","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.jaad.2024.01.081","article-title":"Assessment of effectiveness of COVID-19 pandemic scheduling triage in an academic dermatology clinic.","volume":"90","author":"Tabatabai","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"zoi241131r14","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2020.104734","article-title":"Emergency changes in international guidelines on treatment for head and neck cancer patients during the COVID-19 pandemic.","volume":"107","author":"Chaves","year":"2020","journal-title":"Oral Oncol"},{"issue":"6","key":"zoi241131r15","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1200\/OP.20.00218","article-title":"Cancer treatment adaptations in the COVID-19 era.","volume":"16","author":"Waisberg","year":"2020","journal-title":"JCO Oncol Pract"},{"issue":"8","key":"zoi241131r16","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1200\/OP.20.00229","article-title":"Practical considerations for treating patients with cancer in the COVID-19 pandemic.","volume":"16","author":"Segelov","year":"2020","journal-title":"JCO Oncol Pract"},{"issue":"5","key":"zoi241131r18","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/bimj.201100191","article-title":"Adjusting for reporting delay in cancer incidence when combining different sets of cancer registries.","volume":"55","author":"Huang","year":"2013","journal-title":"Biom J"},{"key":"zoi241131r19","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6942e1","article-title":"Race, ethnicity, and age trends in persons who died from COVID-19\u2014United States, May-August 2020.","author":"Gold","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"zoi241131r20","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3322\/canjclin.54.2.78","article-title":"Cancer disparities by race\/ethnicity and socioeconomic status.","volume":"54","author":"Ward","year":"2004","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"zoi241131r21","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1177\/0962280206070621","article-title":"Efficient interval estimation for age-adjusted cancer rates.","volume":"15","author":"Tiwari","year":"2006","journal-title":"Stat Methods Med Res"},{"issue":"4","key":"zoi241131r22","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s10552-008-9256-0","article-title":"Impact of socioeconomic status on cancer incidence and stage at diagnosis: selected findings from the surveillance, epidemiology, and end results: National Longitudinal Mortality Study.","volume":"20","author":"Clegg","year":"2009","journal-title":"Cancer Causes Control"},{"issue":"3","key":"zoi241131r23","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z","article-title":"Permutation tests for joinpoint regression with applications to cancer rates.","volume":"19","author":"Kim","year":"2000","journal-title":"Stat Med"},{"issue":"27","key":"zoi241131r24","doi-asserted-by":"crossref","first-page":"4352","DOI":"10.1200\/JCO.22.02170","article-title":"Cancer screening in the United States during the second year of the COVID-19 pandemic.","volume":"41","author":"Star","year":"2023","journal-title":"J Clin Oncol"},{"key":"zoi241131r25","doi-asserted-by":"crossref","DOI":"10.1016\/j.scitotenv.2021.146334","article-title":"Urban environments and COVID-19 in three Eastern states of the United States.","volume":"779","author":"Lee","year":"2021","journal-title":"Sci Total Environ"},{"issue":"7","key":"zoi241131r26","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1200\/OP.20.00352","article-title":"Rural cancer disparities in the United States: a multilevel framework to improve access to care and patient outcomes.","volume":"16","author":"Yabroff","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"zoi241131r17"},{"key":"zoi241131r27","unstructured":"National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Accessed April 7, 2024. https:\/\/seer.cancer.gov\/"},{"key":"zoi241131r28","unstructured":"Cancer Statistics Center. Explore cancer statistics. American Cancer Society. Accessed September 3, 2024. https:\/\/cancerstatisticscenter.cancer.org\/#\/"},{"key":"zoi241131r29","unstructured":"Centers for Disease Control and Prevention. About US cancer statistics. Updated June 13, 2024. Accessed September 3, 2024. https:\/\/www.cdc.gov\/united-states-cancer-statistics\/about\/index.html"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2824734\/kim_2024_oi_241131_1727892289.94156.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T15:01:14Z","timestamp":1728918074000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2824734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,14]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.39263","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,14]]}}}